PharmaFocus Today – Page 18 – media

China Biopharmaceutical and Indonesia’s Tempo Scan establish a joint venture with China Biopharmaceutical holding a 51% stake to expand the Southeast Asian pharmaceutical market

On July 27, China Biopharmaceutical (01177) announced that it had signed a joint venture agreement with Indonesian listed company PT Tempo Scan Pacific Tbk (Tempo Scan) to jointly establish a joint venture company PT TEMPO CTTQ BIOPHARMACEUTICAL INDONESIA (TCBI). Sino Biopharmaceutical holds a 51% stake in TCBI, while Tempo Scan holds a 49% stake. The joint venture will combine Sino Biopharmaceutical’s strengths in innovative R&D and product pipeline with Tempo Scan’s localized capabilities in Indonesia, including manufacturing, regulatory registration, market access, sales and marketing, and distribution networks. The announcement stated that both parties are currently advancing multiple specialty drugs and innovative drugs.The registration and listing process has been completed, with some products already approved and several others under review. In addition to commercial cooperation, both parties will continue to explore further cooperation opportunities, including academic exchanges, local clinical development, production technology transfer, and future localized production. The establishment of the ...
- Source: drugdu
- 168
- July 31, 2026
Subsidiary’s application for clinical trial registration of GenSci144 tablets for domestic production approved

People’s Finance News, July 30th – Changchun High & New Technology Industries Group Co., Ltd.(000661) announced on July 30 that its subsidiary, Jinsai Pharmaceutical, recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, and the application for registration of the domestic production of GenSci144 tablets by Jinsai Pharmaceutical has been approved. GenSci144 tablets are an oral small molecule inhibitor targeting the neutral amino acid transporter SLC6A19, independently developed by Jinsai Pharmaceutical. It is registered as a Class 1 chemical drug and is intended for the treatment of chronic kidney disease (CKD). https://finance.eastmoney.com/a/202607303826738322.html
- Source: drugdu
- 186
- July 31, 2026
Degludec Insulin Injection Receives Marketing Approval

On July 30, Dongyangguang Pharmaceutical (06887) announced that its independently developed insulin degludec injection has received marketing approval from the National Medical Products Administration (NMPA). The drug is available in both cartridge and pre-filled injection pen versions. Insulin degludec injection is a fourth-generation long-acting basal insulin analog with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, allowing for once-daily dosing to meet the entire day’s basal insulin requirements. Furthermore, this drug is superior to insulin glargine in terms of glucose-lowering curve stability and the incidence of hypoglycemia. With the launch of insulin degludec injection, the company now offers six insulin products in the Chinese market, covering three major clinical application scenarios: basal, prandial, and premixed insulin. The company is also pursuing international registration for other insulin products to expand its international market share. https://finance.eastmoney.com/a/202607303826929962.html
- Source: drugdu
- 170
- July 31, 2026
The king of valves’ revenue exceeded expectations, with TMTT surging by 47%!

Edwards Life Sciences recently announced its second-quarter results, with revenue of $1.74 billion, a 13.6% year-over-year increase, representing a significant growth.However, it’s worth noting that net profit performance contrasts sharply with revenue growth. Net profit for the period was $241.9 million, a 27.4% year-over-year decline. Nevertheless, looking at each business segment, Edwards’ core business remains solid. As Edwards’ core business, transcatheter aortic valve replacement (TAVR) sales reached $1.3 billion in the second quarter, up 11.3% year-over-year. This business accounts for approximately 75% of the company’s total revenue and remains its absolute pillar. Edwards attributed the growth of TAVR to continued clinical momentum and evidence-based support for active disease management of aortic stenosis. The company specifically highlighted the differentiated advantages of its Sapien TAVR platform, namely the 7-year follow-up data from the PARTNER 3 trial presented at the recent New York Heart Valve Conference, and the latest findings from the EARLY ...
- Source: drugdu
- 216
- July 27, 2026
A neurosurgical robotics company has officially announced its latest appointment!

AiM Medical Robotics recently announced the appointment of Andrew “Andy” Aberdale as the company’s new president and chief financial officer. Founded in 2018, AiM Medical Robotics is a company focused on neurosurgical robots, dedicated to developing surgical robot technologies that enable precise neurosurgical procedures to be performed directly under magnetic resonance imaging. Its platform utilizes a combination of intraoperative real-time magnetic resonance imaging and robot guidance in neurosurgical systems to ensure precise implantation of neurostimulation electrodes for Parkinson’s disease patients. The platform has also been extended to a range of craniocerebral surgeries, such as biopsies, tumor ablation, and targeted intracranial delivery of novel therapies. It is understood that Andy, the newly appointed leader, has over thirty years of experience in operations and finance leadership. His past experience includes successfully commercializing early-stage startups and achieving smooth exits, as well as executing high-value exits and driving rapid organizational growth. According to the ...
- Source: drugdu
- 183
- July 27, 2026
Despite positive news, the stock price fell after Watson Bio’s bivalent HPV vaccine received marketing authorization in Tanzania.

On July 23, an announcement from Watson Bio ( 300142.SZ ) attracted market attention. The bivalent HPV vaccine WALRINVAX (vial specification) produced by the subsidiary Yuxi Zerun has obtained a drug registration certificate issued by the Tanzania Medicines and Medical Devices Authority and is approved for marketing in the local market. This is not a simple news story about “going global”. Watson Bio’s Tanzanian registration certificate is both an “entry ticket” to the African market and a “must-answer question” regarding its commercialization capabilities. The positive announcement contradicted the stock price movement. On July 23, Watson Bio closed at 13.26 yuan, down 1.70%. image.png On July 24, the decline further widened, hitting a low of 12.72 yuan during the session. By the morning close, the stock was trading at 12.83 yuan, a drop of 3.24%. Other data showed that the stock price once fell to 12.75 yuan, a drop of as ...
- Source: drugdu
- 256
- July 27, 2026
Gan & Lee Pharmaceuticals’ Aspart Insulin 30 Injection Approved in India, Breaking Long-Term Monopoly of Original Drug Manufacturers

Recently, Gan & Lee Pharmaceuticals (stock code: 603087.SH) announced that its Aspart Insulin 30 Injection has officially obtained import marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) of India, becoming the first approved biosimilar of Aspart Insulin 30 Injection in India. Breaking the monopoly of original research drugs and solving the problem of accessibility to diabetes diagnosis and treatment in India. India has one of the largest diabetes populations in the world. According to the latest data from the International Diabetes Federation (IDF), there are approximately 89.83 million people aged 20-79 with diabetes in India, a number projected to rise to 157 million by 2050, representing a growth rate of 75% .<sup> 1 </sup> With the continued growth of the local diabetes population, the market demand for high-quality, readily available insulin products is increasingly urgent. However, the supply of aspart insulin 30 injection in India has long relied ...
- Source: drugdu
- 212
- July 27, 2026
Paliperidone Palmate Injection from CSPC Pharmaceutical Group Approved for Marketing

On July 24, CSPC Pharmaceutical Group (1093.HK) announced that its independently developed second-generation antipsychotic long-acting injection, paliperidone palmitate injection (specifications include: (1) 0.75ml:75mg; (2) 1.0ml:100mg; (3) 1.5ml:150mg (calculated as C 23 H 27 FN 4 O 3 ) (hereinafter referred to as “the product”), has been approved for marketing by the National Medical Products Administration of the People’s Republic of China and is suitable for the treatment of acute and maintenance phases of schizophrenia. Compared to traditional antipsychotic drugs, this product only needs to be administered once a month, and it takes effect quickly after administration, requiring no oral medication supplementation. It can be used to treat patients in the acute phase. At the same time, monthly administration significantly improves patient medication adherence, avoids missed doses, and effectively reduces the relapse rate and readmission rate. This product is listed as a recommended medication in authoritative domestic and international treatment guidelines ...
- Source: drugdu
- 241
- July 27, 2026
FDA approves first ophthalmic bevacizumab for market.

On July 24, Outlook Therapeutics announced that ONS-5010 (bevacizumab, brand name: Lytenava) received FDA approval for the treatment of wet age-related macular degeneration (wAMD). This is the first ophthalmic bevacizumab formulation approved by the FDA. The original bevacizumab ( Avastin ) is an anti-VEGF-A monoclonal antibody developed by Roche and is currently only indicated for cancer patients. ONS-5010 has completed four Phase III studies to date, including NORSE ONE, NORSE TWO, NORSE THREE, and NORSE EIGHT . NORSE ONE was a proof-of-concept study that included 61 patients with wAMD. The results showed that the proportion of patients in the ONS-5010 group who achieved an increase of more than 15 letters in their best corrected visual acuity (BCVA) score was not significantly different from that in the ranibizumab group (11.8% vs. 22%).The NORSE TWO study included 228 patients with wAMD. Results showed that the proportion of patients achieving an increase of ...
- Source: drugdu
- 149
- July 27, 2026
Chinese innovative drugs score a Blockbuster Deal! AstraZeneca buys out Suvolotinib for $1.5 billion

Originally produced by Yang Xixia, Jianshi Bureau, July 14, 2026 20:24 Beijing On July 14, China’s innovative drug industry saw another major deal: ج Dizal Pharma willgrant AstraZeneca the exclusive global development and commercialization rights to suvolotinib. AstraZeneca will pay Dizal Pharma a $600 million upfront payment and $900 million in milestone payments, with clinical development and sales milestones capped at $400 million and $500 million, respectively. Simply put, AstraZenecabought out suvolotinib outright for $1.5 billion. As soon as the news broke, Dizal Pharma’s stock surged 20CM in the afternoon. The capital market recognized the certainty of this deal. Unlike other BD deals that often run into the billions of dollars, Dizhe’s $1.5 billion total may not be large, but the $600 million upfront payment is real cash in hand, and the future milestone payments are also highly certain. This is the fundamental reason the market is willing to pay ...
- Source: drugdu
- 240
- July 15, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.